• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含屈螺酮的口服避孕药不影响葡萄糖调节和循环皮质酮。

Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone.

作者信息

Adeyanju Oluwaseun A, Olatunji Lawrence A

机构信息

Department of Physiology, College of Health Sciences, University of Ilorin, Ilorin 240003, Nigeria.

Cardiometabolic Research Unit, Department of Physiology, Afe Babalola University, Ado-Ekiti, Nigeria.

出版信息

J Basic Clin Physiol Pharmacol. 2019 Aug 30;30(5):jbcpp-2018-0184. doi: 10.1515/jbcpp-2018-0184.

DOI:10.1515/jbcpp-2018-0184
PMID:31469652
Abstract

Background Combined oral contraceptive (COC) use has been associated with an increased risk of insulin resistance (IR) and other adverse cardiovascular events, despite efforts to reduce the dosage and/or progestin type. COC containing drospirenone (DRSP) is an analog of spironolactone, hence its antimineralocorticoid and antiandrogenic characteristics have been deemed beneficial, although the benefits and/or negative outcome of its usage have not been fully elucidated. We therefore hypothesized that COC with DRSP component will not affect glucose regulation and circulating corticosterone. Method Ten-week-old female Wistar rats were divided into three groups: control (CON), ethinylestradiol/drospirenone COC (EE/DRSP)-treated, and ethinylestradiol/levonorgestrel COC (EE/LN)-treated rats. The treatment lasted for 8 weeks. Results Results showed that with the exception of lipid profiles, EE/LN but not EE/DRSP COC treatment affected body weight, glucose tolerance, plasma insulin, corticosterone, (IR), and pancreatic β-cell dysfunction. Conclusion Taken together, the findings showed that the beneficial effect of EE/DRSP could possibly be through the DRSP component. The result also implies that COCs containing DRSP may be a better and safer means of contraception than those with LN with less cardiovascular risks.

摘要

背景 尽管一直在努力降低剂量和/或改变孕激素类型,但复方口服避孕药(COC)的使用仍与胰岛素抵抗(IR)风险增加及其他不良心血管事件相关。含屈螺酮(DRSP)的COC是螺内酯的类似物,因此其抗盐皮质激素和抗雄激素特性被认为有益,尽管其使用的益处和/或负面结果尚未完全阐明。因此,我们假设含DRSP成分的COC不会影响葡萄糖调节和循环皮质酮水平。方法 将10周龄雌性Wistar大鼠分为三组:对照组(CON)、接受乙炔雌二醇/屈螺酮COC(EE/DRSP)治疗组和接受乙炔雌二醇/左炔诺孕酮COC(EE/LN)治疗组。治疗持续8周。结果 结果显示,除血脂谱外,EE/LN而非EE/DRSP COC治疗会影响体重、糖耐量、血浆胰岛素、皮质酮、胰岛素抵抗(IR)和胰腺β细胞功能障碍。结论 综上所述,研究结果表明EE/DRSP的有益作用可能是通过DRSP成分实现的。该结果还意味着,含DRSP的COC可能是一种比含LN的COC更好、更安全的避孕方式,心血管风险更低。

相似文献

1
Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone.含屈螺酮的口服避孕药不影响葡萄糖调节和循环皮质酮。
J Basic Clin Physiol Pharmacol. 2019 Aug 30;30(5):jbcpp-2018-0184. doi: 10.1515/jbcpp-2018-0184.
2
Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.一种含有抗盐皮质激素孕激素屈螺酮的新型口服避孕药对肾素-醛固酮系统、体重、血压、糖耐量和脂质代谢的影响。
J Clin Endocrinol Metab. 1995 Jun;80(6):1816-21. doi: 10.1210/jcem.80.6.7775629.
3
Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.静脉血栓栓塞风险与含地诺孕素和屈螺酮的口服避孕药的使用:一项德国病例对照研究的结果
J Fam Plann Reprod Health Care. 2010 Jul;36(3):123-9. doi: 10.1783/147118910791749416.
4
Combined oral contraceptive in female mice causes hyperinsulinemia due to β-cell hypersecretion and reduction in insulin clearance.口服避孕药会导致雌性小鼠发生高胰岛素血症,这是由于β细胞分泌过多和胰岛素清除率降低所致。
J Steroid Biochem Mol Biol. 2019 Jun;190:54-63. doi: 10.1016/j.jsbmb.2019.03.018. Epub 2019 Mar 25.
5
Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.评估含有雌三醇和屈螺酮的新型口服避孕药对止血参数的影响。
Contraception. 2020 Dec;102(6):396-402. doi: 10.1016/j.contraception.2020.08.015. Epub 2020 Sep 19.
6
Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.服用炔雌醇/屈螺酮及其他口服避孕药的女性发生高钾血症的风险。
Contraception. 2008 Nov;78(5):377-83. doi: 10.1016/j.contraception.2008.06.012. Epub 2008 Aug 8.
7
Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.炔雌醇/屈螺酮:作为口服避孕药的应用综述
Treat Endocrinol. 2003;2(1):49-70. doi: 10.2165/00024677-200302010-00005.
8
Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?屈螺酮与非致死性静脉血栓栓塞:雌二醇剂量是否存在风险差异?
J Thromb Haemost. 2013 Jun;11(6):1059-68. doi: 10.1111/jth.12224.
9
Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.健康中国女性中口服避孕药屈螺酮炔雌醇(Yasmin)的有效性和安全性:一项随机、开放标签、对照、多中心试验。
Clin Drug Investig. 2010;30(6):387-96. doi: 10.1007/BF03256908.
10
Comparison of change in body weight between contraception containing 30-μg ethinylestradiol/2-mg chlormadinone acetate or 30-μg ethinylestradiol/3-mg drospirenone: a randomised controlled trial.含30μg炔雌醇/2mg醋酸氯地孕酮或30μg炔雌醇/3mg屈螺酮避孕药之间体重变化的比较:一项随机对照试验。
Eur J Contracept Reprod Health Care. 2020 Feb;25(1):43-48. doi: 10.1080/13625187.2019.1688290. Epub 2019 Nov 22.

引用本文的文献

1
Blood glucose lowering and anti-oxidant potential of erythritol: An in vitro and in vivo study.赤藓糖醇的降血糖和抗氧化潜力:一项体外和体内研究。
J Diabetes Metab Disord. 2023 May 29;22(2):1217-1229. doi: 10.1007/s40200-023-01237-x. eCollection 2023 Dec.
2
The benefits of estetrol addition to drospirenone for contraception.在屈螺酮中添加雌三醇用于避孕的益处。
AJOG Glob Rep. 2023 Sep 18;3(4):100266. doi: 10.1016/j.xagr.2023.100266. eCollection 2023 Nov.
3
Evaluating the Cognitive Impacts of Drospirenone, a Spironolactone-Derived Progestin, Independently and in Combination With Ethinyl Estradiol in Ovariectomized Adult Rats.
评估去氧孕烯(一种螺内酯衍生的孕激素)单独及与炔雌醇联合使用对去卵巢成年大鼠认知功能的影响。
Front Neurosci. 2022 May 25;16:885321. doi: 10.3389/fnins.2022.885321. eCollection 2022.